Cloud Top New Excellence (01952.HK) NephroCare has been included in the "Chinese Adult IgA Nephropathy and IgA Vasculitis Clinical Practice Guidelines (Draft Version)".

According to the Securities Times APP, on May 21, YunDingXinYao (01952.HK) announced that NEFECON (Budesonide enteric-coated capsules) has been included in the "Clinical Practice Guidelines for Adult IgA Nephropathy and IgA Vasculitis in China (pre-audit version)", recommending a 9-month course of Budesonide enteric-coated capsules for IgA nephropathy patients at risk of disease progression, regardless of proteinuria levels, to reduce pathogenic IgA (Gd-IgA1) (2B). NEFECON is a targeted therapy for IgA nephropathy that acts on the intestinal mucosa, providing precise efficacy and good safety, offering a new treatment option for IgA nephropathy patients. This marks NEFECON as the only IgA nephropathy targeted therapy drug recommended by both domestic and international guidelines, confirming its leading position as a cornerstone of first-line treatment for IgA nephropathy.